GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » EBITDA per Share

Yubo International Biotech (Yubo International Biotech) EBITDA per Share : $-0.01 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech EBITDA per Share?

Yubo International Biotech's EBITDA per Share for the three months ended in Mar. 2024 was $-0.00. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.01.

During the past 3 years, the average EBITDA per Share Growth Rate was -10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Yubo International Biotech's EBITDA per Share or its related term are showing as below:

YBGJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1   Med: -10.1   Max: -10.1
Current: -10.1

During the past 4 years, the highest 3-Year average EBITDA per Share Growth Rate of Yubo International Biotech was -10.10% per year. The lowest was -10.10% per year. And the median was -10.10% per year.

YBGJ's 3-Year EBITDA Growth Rate is ranked worse than
72.3% of 704 companies
in the Medical Devices & Instruments industry
Industry Median: 7.65 vs YBGJ: -10.10

Yubo International Biotech's EBITDA for the three months ended in Mar. 2024 was $-0.36 Mil.

During the past 3 years, the average EBITDA Growth Rate was -12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 4 years, the highest 3-Year average EBITDA Growth Rate of Yubo International Biotech was -12.90% per year. The lowest was -12.90% per year. And the median was -12.90% per year.


Yubo International Biotech EBITDA per Share Historical Data

The historical data trend for Yubo International Biotech's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yubo International Biotech EBITDA per Share Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA per Share
-0.01 -0.01 -0.01 -0.01

Yubo International Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Yubo International Biotech EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Yubo International Biotech's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA per Share(A: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-1.005/119.821
=-0.01

Yubo International Biotech's EBITDA per Share for the quarter that ended in Mar. 2024 is calculated as

EBITDA per Share(Q: Mar. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.363/119.821
=-0.00

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yubo International Biotech  (OTCPK:YBGJ) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Yubo International Biotech EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Yubo International Biotech (Yubo International Biotech) Business Description

Traded in Other Exchanges
N/A
Address
31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.
Executives
Lina Liu 10 percent owner, officer: CFO, Treasurer and Secretary MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui director MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun director, officer: President and CEO MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Yang director MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth director C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc 10 percent owner 8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica officer: Treasurer and Secretary C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff director, officer: Chairman, President, CSO C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman director C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler director C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech (Yubo International Biotech) Headlines

No Headlines